Genetics of Osteogenesis Imperfecta
No Results
No Results
processing….
Osteogenesis imperfecta (OI) is a disorder of bone fragility chiefly caused by mutations in the COL1A1 and COL1A2 genes that encode type I procollagen. Four types of osteogenesis imperfecta were originally described by Sillence in 1979 and are now used broadly as the Sillence Criteria. [1] The Nosology and Classification of Genetic Skeletal Disorders provides similar categorization in the 2010 revision. [2] Precise typing is often difficult, and depends in large degree on the experience of the clinician. Severity ranges from mild forms to lethal forms in the perinatal period. Additional genes have been discovered in which mutations can also cause brittle bones. These are typically clinically indistinguishable and are considered by most to be subtypes of osteogenesis imperfecta. [3] Examples of common radiologic findings of osteogenesis imperfecta are shown in the images below.
The most widely used classification of osteogenesis imperfecta, published by Sillence et al in 1979, does not include additional forms of the disorder, which were discovered as a result of improvements in molecular diagnostics. [4] Rather, these forms of osteogenesis imperfecta are caused by genes that interact with collagen I or in the complex relationship between formation and remodeling of bone. They are molecularly distinct from osteogenesis imperfecta caused by COL1A1 or COL1A2 but form an example of locus heterogeneity. Forlino and Marini, in 2015, offered an alternate way of understanding the genetics of osteogenesis imperfecta, using five functional categories, as follows [5] :
This classfication system has not been integrated into widespread use but offers significant streamlining of categories into intellectually satisfying divisions.
Type I collagen fibers are found in the bones, organ capsules, fascia, cornea, sclera, tendons, meninges, and dermis. Type I collagen, which constitutes approximately 30% of the human body by weight, (90% of the protein within bone) is defective in osteogenesis imperfecta. In structural terms, type I collagen fibers are composed of a left-handed helix formed by intertwining of pro-alpha 1 and pro-alpha 2 chains. Mutations in the genes that encode these chains cause osteogenesis imperfecta (COL1A1 at 17q21 and COL1A2 at 7q22.1, respectively).
Qualitative defects (eg, an abnormal collagen I molecule) and quantitative defects (eg, decreased production of normal collagen I molecules) are described. Quantitative defects most frequently result from missense mutations in a glycine-coding codon and cause disease due to a dominant negative effect. There is not a perfect correlation between genotype and phenotype, but a few observations have been made. First, generally speaking mutations in the COL1A1 gene will tend to be more severe than a corresponding mutation in the COL1A2 gene, likely due to the fact that that two alpha 1 chains are required and only one alpha 2 chain is required to make the procollagen I heterotrimer. Second, mutations located at the carboxyl terminal domain of each of the genes are more severe than in other domains. In particular, missense mutations in COL1A1 in this region are frequently (but not always) lethal. Third, size and polarity matter to the severity of the mutation. As an example, a substitution of glycine for alanine, which is only slightly larger, nonpolar, and with similar chemical properties, is likely to result in a milder phenotype. Contrast this with a substitution of glycine for glutamic acid at the same position, which is large, negatively charged, and with different chemical properties and is more likely to be severe or even lethal. Quantitative defects often result from nonsense mutations but can result from larger deletions in one of the procollagen genes and cause disease due to haploinsufficiency effect, as the prematurely truncated mRNA undergoes nonsense-mediated decay (NMD); while the patient is left with structurally normal collagen, he or she makes only half the normal amount. These patients have mild nondeforming (Type I) osteogenesis imperfecta.
A study by Balasubramanian et al indicated that COL1A1/COL1A2 mutations consistently result in collagen fibril diameter variability and collagen flowers. [6]
Patients with this form of osteogenesis imperfecta generally have moderate severity disease but frequently develop hyperplastic calluses in long bones after having a fracture or orthopedic surgery that involves osteotomies. The size and shape of the callus may remain stable for many years after a rapid growth period, but in some cases slowly involutes. Patients also frequently develop calcification of the forearm interosseous membrane and dislocation of the radial head, which results in difficulities with supination and pronation. They may also have subphyseal metaphyseal radiodensity seen on radiography. [7] This condition is caused by heterozygous mutations in the IFITM5 gene, and inheritance is autosomal dominant. [8]
Histology of bone showed that the lamellae are arranged in an irregular fashion and in some cases appeared meshlike, as opposed to the typical parallel arrangement in patients with osteogenesis imperfecta.
SERPINFI (Type VI)
Patients with this form of osteogenesis imperfecta generally have moderate severity disease. It was observed that many patients with this form of osteogenesis imperfecta do not have fractures at birth and only develop them later in infancy or as toddlers. Patients with this form of osteogenesis imperfecta have been described as having variably blue or white sclerae and have normal teeth. [9] This condition is caused by homozygous mutation in the SERPINF1 gene, and inheritance is autosomal recessive. [10]
Histology of bone showed a characteristic fish-scale appearance to the lamellae and at least one author has commented on the presence of large quantities of unmineralized osteoid on biopsy specimens.
CRTAP/LEPRE1/PPIB (Types VII-IX)
Patients with osteogenesis imperfecta caused by mutations in these three genes generally have severe disease, with examples of lethal disease being noted. Cartilage-associated protein (CRTAP) is a protein required for prolyl 3-hydroxylation, and with the protein products of the LEPRE1 and PPIB genes, forms a heterotrimeric protein that is crucial for proper posttranslational modification of collagen I. Osteogenesis imperfecta caused by mutations in CRTAP have been designated type VII disease, whereas osteogenesis imperfecta caused by mutations in LEPRE1 and PPIB are designated type VIII and type IX disease, respectively. [11] These conditions are caused by homozygous or compound heterozygous mutations and are inherited in an autosomal recessive manner.
SERPINH1 (Type X)
Report of only one patient with this form of osteogenesis imperfecta could be found in the literature. This male patient was born to a consanguineous union of Saudi Arabian origin, and his parents were reported as clinically normal. He was reported to have severe deforming osteogenesis imperfecta with dentinogenesis imperfecta, nephrocalcinosis, and chronic lung disease. He died at age 3 years from respiratory complications. Genetic testing of this child found a previously described homozygous mutation in the SERPINH1 gene. [12] The protein product of SERPINH1 is a chaperone in the ER that appears to function in collagen trafficking.
FKBP10 (Type XI)
A small number of patients with this form of osteogenesis imperfecta have been reported and severity has been moderate to severe. It is caused by homozygous mutations in the FKBP10 gene and is inherited in an autosomal recessive manner. [13] It is understood that some patients with Bruck syndrome, type II also have mutations in this gene, but the full spectrum of clinical findings is not understood, and it has been proposed to designate FKBP10 -related disorders as recessive forms of progressive deforming osteogenesis imperfecta with or without joint contractures. [14] The protein product of FKBP10 is a chaperone that participates in collagen folding and mutation impairs its secretion. [15]
Histology of bone showed a distorted lamellar structure and a fish scale pattern.
SP7 (Type XII)
Only one patient with this form of osteogenesis imperfecta has been reported and had moderate severity disease. This male patient was the product of a second-cousin union and in addition to fractures had delay in tooth eruption, normal hearing, and white sclerae. A sibling was similarly affected, but also died of a presumably unrelated congenital heart defect. The surviving child had homozygous deletions in the SP7 gene, and this form of osteogenesis imperfecta is inherited in an autosomal recessive fashion. [16] The protein product of SP7 is required for osteoblast differentiation and bone formation. In a null mutant animal model, no cortical bone or bone trebeculae were formed through intramembraneous or endochondral ossification. [17]
BMP1 (Type XIII)
A small number of patients with this form of osteogenesis imperfecta have been described and have generally had severe disease with frequent fractures and severe growth deficiency. However, two siblings described had only borderline low bone density. Patients with this form of osteogenesis imperfecta were described with normal teeth and blue sclerae. [18] This form of osteogenesis imperfecta is caused by homozyous mutation in the BMP1 gene, and it is inherited in an autosomal recessive manner. The BMP1 protein product appears to play important roles in osteogenesis, but also is thought to have a role in the removal of C-propeptides from certain procollagens, including type I procollagen. [19]
TMEM38B (Type XIV)
This form of osteogenesis imperfecta has been described in three consanguineous families of Saudi origin, and three different consanguineous families of Israeli Bedouin origin. Affected individuals had osteogenesis imperfecta of variable severity without blue sclerae, dentinogenesis imperfecta, or hearing loss. [20] This form of OI is caused by homozygous mutation in the TMEM38B gene and is inherited in an autosomal recessive manner. [21]
WNT1 (Type XV)
This recently discovered form of osteogenesis imperfecta has now been described in a number of families and causes moderate to severe disease. Patients with this condition have had short stature, blue or white sclerae, and normal hearing. A subset of patients have been seen with brain malformations and developmental delay. This form of OI is caused by homozygous or compound heterozygous mutations in the WNT1 gene and is inherited in an autosomal recessive manner. [22] Canonical WNT/beta-catenin signaling has been shown to be crucial for the differentiation of osteoblasts and further bone development. [23]
CREB3L1 (Type XVI)
CREB3L1 encodes the endoplasmic reticulum stress transduser protein OASIS, which regulates the expression of type 1 procollagen. Biallelic mutation in this gene can be expected to produce insufficiency of type I procollagen. Two siblings have been reported with this form of OI, and both were homozygous for the same deletion. This deletion is some 91 kB in size and renders patients nullisomic for the CREB3L1 locus. The first affected patient was male and was known to be affected by severe OI. This patient was small for gestational age, with multiple fractures in utero. Postnatally, he developed a number of fractures and was described with beaded ribs. He also had several bouts of pneumonia and died at 9 age months, presumably from respiratory complications, although this was not explicitly stated. The second affected sibling was also male and termination was performed at 19 weeks of gestation. The parents and a healthy older sister did not have similar findings of bone fragility but were described with blue sclerae. The mother had velvety skin and small-joint hypermobility. The father also had velvety skin, as well as conductive hearing loss. [24]
SPARC (Type XVII)
SPARC (secreted protein, acidic, cysteine-rich) is a glycoprotein that binds to multiple matrix proteins, including collagen I. Two unrelated patients have been described as homozygous for pathogenic variants in the SPARC gene; both had significant bone fragility and had been previously diagnosed with Type IV OI based on phenotype alone. The first patient was of North African origin and in addition to her fractures, experienced a neonatal intraventricular hemorrhage. At the time of her evaluation by the authors, she had sustained 10 long-bone fractures but was of normal stature. She had joint hypermobility and humeral bowing, and her bone mineral density was low for her age. The second patient was born of a consanguineous union and was of Indian descent. She presented initially with hip dislocation and was subsequently observed to have hypotonia and motor delay. She also had normal stature, as well as joint laxity and soft skin. Her bone mineral density was also low for her age. Molecular diagnosis was obtained in these patients using whole exome sequencing (WES). The first patient was homozygous for the pathogenic variant c.497G>A (p.Arg166His), and the second patient was homozygous for the pathogenic variant c.787G>A (p.Glu263Lys). It was observed that these pathogenic variants were both in highly conserved regions of the protein. Further investigation revealed that each was located in different portions of the extracellular collagen binding portion of the SPARC protein. [25]
Patients with Bruck syndrome have congenital brittle bones prone to fracture, as well as congenital joint contractures and pterygia. They also have short stature, severe limb deformity, wormian bones, and progressive scoliosis which can be severe. Patients have generally been described with normal hearing, no dentinogenesis imperfecta, and white sclerae. Two forms of Bruck syndrome have been delinated with molecular testing, but appear to be clinically indistinguishable. Bruck syndrome 1 is caused by homozygous mutation in the FKBP10 gene [26] , while Bruck syndrome 2 is caused by homozygous mutation in the PLOD2 gene. [27] Both disorders are inherited in an autosomal recessive manner. It has been suggested that the defect underlying Bruck syndrome is a deficiency of bone-specific telopeptide lysyl hydroxylase, which results in aberrant bone collagen crosslinking. [28]
United States
The prevalence of OI is estimated to be 1 per 15,000 live births [29] ; however, the mild form is underdiagnosed, and the actual prevalence may be higher.
International
Prevalence appears to be similar worldwide, although there may be an increased risk of recessive forms of osteogenesis imperfecta in populations with high degree of consanguinity.
No differences based on race are reported.
No differences based on sex are reported.
The age when symptoms (ie, fractures) begin widely varies. Patients with mild forms may not have fractures until adulthood, or they may present with fractures in infancy. Patients with severe cases typically present with fractures in utero.
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr. 16(2):101-16. [Medline].
Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011 May. 155A(5):943-68. [Medline].
Shaker JL, Albert C, Fritz J, Harris G. Recent developments in osteogenesis imperfecta. F1000Res. 2015. 4 (F1000 Faculty Rev):681. [Medline]. [Full Text].
Van Dijk FS, Sillence DO. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014 Apr 8. [Medline].
Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016 Apr 16. 387 (10028):1657-71. [Medline].
Balasubramanian M Md, Sobey GJ FCDerm, Wagner BE BSc Hons, et al. Osteogenesis imperfecta: Ultrastructural and histological findings on examination of skin revealing novel insights into genotype-phenotype correlation. Ultrastruct Pathol. 2016 Feb 10. 1-6. [Medline].
Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000 Sep. 15(9):1650-8. [Medline].
Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012 Aug 10. 91(2):343-8. [Medline]. [Full Text].
Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002 Jan. 17(1):30-8. [Medline].
Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011 Mar 11. 88(3):362-71. [Medline]. [Full Text].
Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006 Dec 28. 355(26):2757-64. [Medline].
Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Mar 12. 86(3):389-98. [Medline]. [Full Text].
Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Apr 9. 86(4):551-9. [Medline]. [Full Text].
Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, et al. Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res. 2011 Mar. 26(3):666-72. [Medline]. [Full Text].
Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL, Leikin S, et al. Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. Hum Mutat. 2012 Nov. 33(11):1589-98. [Medline]. [Full Text].
Lapunzina P, Aglan M, Temtamy S, Caparrós-Martín JA, Valencia M, Letón R, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Jul 9. 87(1):110-4. [Medline]. [Full Text].
Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002 Jan 11. 108(1):17-29. [Medline].
Martínez-Glez V, Valencia M, Caparrós-Martín JA, Aglan M, Temtamy S, Tenorio J, et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat. 2012 Feb. 33(2):343-50. [Medline]. [Full Text].
Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet. 2012 Apr 6. 90(4):661-74. [Medline]. [Full Text].
Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N, Mousa N, et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet. 2012 Oct. 49(10):630-5. [Medline].
Volodarsky M, Markus B, Cohen I, Staretz-Chacham O, Flusser H, Landau D, et al. A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta. Hum Mutat. 2013 Apr. 34(4):582-6. [Medline].
Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet. 2013 Apr 4. 92(4):565-74. [Medline]. [Full Text].
Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013 Apr 4. 92(4):590-7. [Medline]. [Full Text].
Symoens S, Malfait F, D’hondt S, et al. Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet J Rare Dis. 2013 Sep 30. 8:154. [Medline].
Mendoza-Londono R, Fahiminiya S, Majewski J, et al. Recessive osteogenesis imperfecta caused by missense mutations in SPARC. Am J Hum Genet. 2015 Jun 4. 96 (6):979-85. [Medline].
Shaheen R, Al-Owain M, Faqeih E, Al-Hashmi N, Awaji A, Al-Zayed Z, et al. Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. Am J Med Genet A. 2011 Jun. 155A(6):1448-52. [Medline].
Puig-Hervás MT, Temtamy S, Aglan M, Valencia M, Martínez-Glez V, Ballesta-Martínez MJ, et al. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome–osteogenesis imperfecta phenotypic spectrum. Hum Mutat. 2012 Oct. 33(10):1444-9. [Medline].
Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, van der Sluijs HA, et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci U S A. 1999 Feb 2. 96(3):1054-8. [Medline]. [Full Text].
Kuurila K, Kaitila I, Johansson R, Grénman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol. 2002 Oct. 111(10):939-46. [Medline].
Santos F, McCall AA, Chien W, Merchant S. Otopathology in Osteogenesis Imperfecta. Otol Neurotol. 2012 Dec. 33(9):1562-6. [Medline]. [Full Text].
Jain M, Tam A, Shapiro JR, et al. Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med. 2018 Jul 4. [Medline].
Pillion JP, Shapiro J. Audiological findings in osteogenesis imperfecta. J Am Acad Audiol. 2008 Sep. 19(8):595-601. [Medline].
Basal S, Ozgok Y, Tahmaz L, Atim A, Zor M, Bilgic S, et al. Extraperitoneal laparoscopy-assisted percutaneous nephrolithotomy in a patient with osteogenesis imperfecta. Urol Res. 2011 Feb. 39(1):73-6. [Medline].
Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone hystomorphometry in children with osteogenesis imperfecta. Bone. 2000. 26:581-9. [Medline].
Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in Children and Adolescents with Osteogenesis Imperfecta: Effect of Treatment Discontinuation. J Clin Endocrinol Metab. 2006. 91:1268-74. [Medline].
Castillo H, Samson-Fang L,. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009 Jan. 51(1):17-29. [Medline].
Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta. Connect Tissue Res. 2010 Jan 6. [Medline].
Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012 Sep. 12 (3):183-8. [Medline].
Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014 Sep 26. 9:145. [Medline].
Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008 Feb. 20(1):52-7. [Medline].
Janus GJ, Finidori G, Engelbert RH, Pouliquen M, Pruijs JE. Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J. 2000 Dec. 9(6):486-91. [Medline]. [Full Text].
[Guideline] Mueller B, Engelbert R, Baratta-Ziska F, et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J Rare Dis. 2018 Sep 10. 13 (1):158. [Medline]. [Full Text].
Sasaki-Adams D, Kulkarni A, Rutka J, Dirks P, Taylor M, Drake JM. Neurosurgical implications of osteogenesis imperfecta in children. Report of 4 cases. J Neurosurg Pediatr. 2008 Mar. 1(3):229-36. [Medline].
Eric T Rush, MD, FAAP, FACMG Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Clinical Geneticist, Children’s Mercy Hospital of Kansas City
Eric T Rush, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American College of Physicians, American Society for Bone and Mineral Research
Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Ultragenyx Pharmaceutical, and Biomarin Pharmaceuticals<br/>Honoraria for: Alexion Pharmaceuticals, Biomarin Pharmaceuticals.
Horacio B Plotkin, MD, FAAP Chief Medical Officer, Retrophin, Inc; Adjunct Associate Professor of Pediatrics and Orthopedic Surgery, University of Nebraska College of Medicine
Horacio B Plotkin, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Received salary from PPD, Inc for: PPD.
Luis O Rohena, MD, FAAP, FACMG Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio
Luis O Rohena, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics
Disclosure: Nothing to disclose.
The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Horatio Plotkin, MD, FAAP, to the development and writing of this article.
Erawati V Bawle, MD, FAAP, FACMG Retired Professor, Department of Pediatrics, Wayne State University School of Medicine
Erawati V Bawle, MD, FAAP, FACMG is a member of the following medical societies: American College of Medical Genetics and American Society of Human Genetics
Disclosure: Nothing to disclose.
Alexander A Cacciarelli, MD, FACR Consulting Staff, Department of Radiology, St Joseph’s Hospital and Medical Center of Phoenix
Disclosure: Nothing to disclose.
Mandar A Pattekar, MD, MS Consulting Staff, Department of Radiology, Methodist Hospital
Disclosure: Nothing to disclose.
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Genetics of Osteogenesis Imperfecta
Research & References of Genetics of Osteogenesis Imperfecta|A&C Accounting And Tax Services
Source
0 Comments